Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472769 · ClinicalTrials.gov registry record · Phase 2
IBP-9414 for the Prevention of Necrotizing Enterocolitis
A Phase 2 study of Necrotizing Enterocolitis, sponsored by Infant Bacterial Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 15
- Study locations
NCT02472769: Completed Phase 2 study of Necrotizing Enterocolitis, sponsored by Infant Bacterial Therapeutics.
NCT02472769 is a Phase 2 study of Necrotizing Enterocolitis that has completed, run by Infant Bacterial Therapeutics. The registered enrollment target is 120 participants, below the 305-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (61% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02472769, a Phase 2 study of Necrotizing Enterocolitis, has completed, sponsored by Infant Bacterial Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 15
- Study locations
Study Summary
Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IBP-9414
Study Locations (15)
Florida
- University Florida Health - Gainesville
- Wolfson Children´s Hospital - Jacksonville
- UF Health Jacksonville - Jacksonville
- Jackson Memorial Hospital - Miami
North Carolina
- Duke University Medical Center - Durham
- Wake Forest University Health Sciences - Winston-Salem
Pennsylvania
- Hahnemann University Hospital - Philadelphia
- Einstein Medical Center of Philadelphia - Philadelphia
Arkansas
- Univ. Arkansas Medical Sciences - Little Rock
California
- UCLA Medical Center - Los Angeles
Indiana
- Memorial Hospital of South Bend - South Bend
Kansas
- Wesley Medical Center - Wichita
New York
- Kings County Hospital Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2017-08-07 |
| Phase | Phase 2 |
What the finished NCT02472769 record still lists
NCT02472769 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 305-participant average among 14 other Necrotizing Enterocolitis trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Necrotizing Enterocolitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02472769 lists 15 locations in 10 states (Florida, North Carolina, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02472769 about?
NCT02472769 is a clinical study titled "IBP-9414 for the Prevention of Necrotizing Enterocolitis". Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.
What is the current status of trial NCT02472769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2016-05-27. Estimated completion is 2017-08-07.
What conditions does trial NCT02472769 study?
This clinical trial studies the following conditions: Necrotizing Enterocolitis.
What interventions are being tested in trial NCT02472769?
The interventions under investigation include: Placebo (DRUG), IBP-9414 (DRUG).
Who is sponsoring clinical trial NCT02472769?
This trial is sponsored by Infant Bacterial Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02472769 being conducted?
This trial has 15 study locations across Arkansas, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Necrotizing Enterocolitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02472769's enrollment target sits among peer trials
120 9th of 14 higher than 6 of 14 other Necrotizing Enterocolitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Necrotizing Enterocolitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RIC-NEC Randomized Controlled Trial
ACTIVE NOT RECRUITING · Phase 2
-
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
COMPLETED · Phase 2
-
Early Predictors of Necrotizing Enterocolitis in Neonates
RECRUITING
-
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis
RECRUITING · Phase 1
-
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
RECRUITING · NA
-
A Cohort Study of the Intestinal Microbiota of Premature Infants
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI